Brant Point Investment Management LLC Buys 7,100 Shares of IDEXX Laboratories, Inc. $IDXX

Brant Point Investment Management LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 255.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,884 shares of the company’s stock after purchasing an additional 7,100 shares during the quarter. IDEXX Laboratories accounts for about 0.8% of Brant Point Investment Management LLC’s holdings, making the stock its 15th biggest holding. Brant Point Investment Management LLC’s holdings in IDEXX Laboratories were worth $6,687,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Virtus Advisers LLC bought a new stake in IDEXX Laboratories during the third quarter valued at approximately $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories during the fourth quarter valued at approximately $29,000. WealthCollab LLC purchased a new position in shares of IDEXX Laboratories during the second quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of IDEXX Laboratories during the third quarter worth approximately $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Up 0.5%

IDXX stock opened at $560.88 on Friday. The company has a market capitalization of $44.24 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98. The company’s 50 day moving average price is $563.06 and its two-hundred day moving average price is $627.69. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm earned $2.91 earnings per share. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on IDXX shares. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. UBS Group decreased their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.